Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability
Authors:
Open Access
- 10 October 2017
- journal article
- research article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 19 (2) , 837-844
Abstract
To ensure consistency of clinical outcomes, orally inhaled therapies must exhibit consistent delivered dose and aerosol properties at the time of manufacturing, throughout storage, and during various patient-use conditions. Achieving consistency across these scenarios has presented a significant challenge, especially for combination products that contain more than one drug. This study characterized the delivered dose and aerosol properties of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI; Bevespi Aerosphere™). GFF MDI, a fixed-dose combination (FDC) of a long-acting muscarinic antagonist, glycopyrrolate (18 μg, equivalent to glycopyrronium 14.4 μg), and a long-acting β2-agonist, formoterol fumarate (9.6 μg; equivalent to formoterol fumarate dihydrate 10 μg), is formulated using innovative co-suspension delivery technology, which suspends micronized drug crystals with spray-dried phospholipid porous particles in hydrofluoroalkane propellant. In this study, delivered dose uniformity was assessed through the labeled number of doses, and aerosol properties, such as percent fine particle fraction (FPF) and mass median aerodynamic diameter, were determined by cascade impaction. GFF MDI achieved reproducible dose delivery and an FPF greater than 55%, whether formulated and delivered as a monocomponent or dual FDC. The performance of GFF MDI was maintained across various manufacturing batches, under extended storage, and with variations in flow rate. Furthermore, unlike a GFF drug crystal-only suspension, drug delivery remained consistent for GFF MDI when simulated patient-handling errors were applied, such as reduced shake energy and delays between shaking and actuation. These results demonstrate that co-suspension delivery technology overcomes well-known sources of variability in MDI drug delivery.Keywords
This publication has 30 references indexed in Scilit:
- Inhaler Devices for Chronic Obstructive Pulmonary Disease: Insights from Patients and Healthcare PractitionersJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2014
- The Global Burden of Respiratory DiseaseAnnals of the American Thoracic Society, 2014
- Advances in Metered Dose Inhaler Technology: Formulation DevelopmentAAPS PharmSciTech, 2014
- Cosuspensions of Microcrystals and Engineered Microparticles for Uniform and Efficient Delivery of Respiratory Therapeutics from Pressurized Metered Dose InhalersLangmuir, 2012
- Inhaler mishandling remains common in real life and is associated with reduced disease controlRespiratory Medicine, 2011
- Not all asthma inhalers are the same: factors to consider when prescribing an inhalerPrimary Care Respiratory Journal, 2009
- Novel hydrofluoroalkane suspension formulations for respiratory drug deliveryExpert Opinion on Drug Delivery, 2005
- Assessment of Handling of Inhaler Devices in Real Life: An Observational Study in 3811 Patients in Primary CareJournal of Aerosol Medicine, 2003
- The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalersAdvanced Drug Delivery Reviews, 2003
- Transition to CFC-free metered dose inhalers — into the new millenniumInternational Journal of Pharmaceutics, 2000